Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Average Rating of “Hold” from Analysts

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) have been assigned an average rating of “Hold” from the five research firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $8.06.

RXRX has been the subject of several analyst reports. Wall Street Zen upgraded shares of Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 29th. Morgan Stanley set a $5.30 target price on shares of Recursion Pharmaceuticals in a research note on Monday, August 17th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Friday, July 17th.

Recursion Pharmaceuticals Trading Up 0.7%

RXRX traded up $0.03 during trading on Friday, reaching $3.56. The company had a trading volume of 2,692,494 shares, compared to its average volume of 17,855,953. The company has a quick ratio of 5.03, a current ratio of 5.03 and a debt-to-equity ratio of 0.01. Recursion Pharmaceuticals has a 52 week low of $2.77 and a 52 week high of $7.18. The stock has a market cap of $1.91 billion, a P/E ratio of -3.43 and a beta of 1.07. The business has a 50 day simple moving average of $3.25 and a 200-day simple moving average of $3.32.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Wednesday, August 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.01). The business had revenue of $7.67 million for the quarter, compared to the consensus estimate of $10.97 million. Recursion Pharmaceuticals had a negative return on equity of 50.41% and a negative net margin of 945.94%.During the same quarter in the previous year, the company earned ($0.41) earnings per share. On average, equities analysts anticipate that Recursion Pharmaceuticals will post -0.92 EPS for the current fiscal year.

Insider Buying and Selling at Recursion Pharmaceuticals

In related news, Director Blake Borgeson sold 30,000 shares of the stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $3.34, for a total transaction of $100,200.00. Following the transaction, the director owned 6,158,287 shares of the company’s stock, valued at approximately $20,568,678.58. This represents a 0.48% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Najat Khan sold 22,408 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $3.52, for a total value of $78,876.16. Following the completion of the transaction, the chief executive officer owned 2,072,890 shares of the company’s stock, valued at approximately $7,296,572.80. This trade represents a 1.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 122,408 shares of company stock valued at $434,976. 6.65% of the stock is owned by insiders.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of RXRX. Norges Bank acquired a new position in shares of Recursion Pharmaceuticals during the 4th quarter worth approximately $23,473,000. Lingotto Investment Management LLP raised its holdings in shares of Recursion Pharmaceuticals by 34.2% in the fourth quarter. Lingotto Investment Management LLP now owns 4,931,057 shares of the company’s stock worth $20,168,000 after acquiring an additional 1,255,980 shares during the last quarter. First Trust Advisors LP lifted its position in shares of Recursion Pharmaceuticals by 15.2% in the first quarter. First Trust Advisors LP now owns 2,610,726 shares of the company’s stock valued at $8,015,000 after acquiring an additional 344,035 shares in the last quarter. Bank of America Corp DE lifted its position in shares of Recursion Pharmaceuticals by 18.2% in the first quarter. Bank of America Corp DE now owns 2,496,831 shares of the company’s stock valued at $7,665,000 after acquiring an additional 384,486 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in shares of Recursion Pharmaceuticals during the first quarter valued at $7,370,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biotechnology company that uses artificial intelligence, automation, and large-scale biological experimentation to accelerate the discovery and development of medicines. Its technology platform, known as the Recursion Operating System, integrates data from biology, chemistry, imaging, and machine learning to identify potential drug candidates and better understand disease biology.

The company develops therapies for areas including oncology, rare diseases, and neurological disorders.